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Intrathecal injection of bombesin (BBS) promoted hypertensive and sympathoexcitatory
effects in normotensive (NT) rats. However, the involvement of rostral ventrolateral
medulla (RVLM) in these responses is still unclear. In the present study, we investigated:
(1) the effects of BBS injected bilaterally into RVLM on cardiorespiratory and sympathetic
activity in NT and spontaneously hypertensive rats (SHR); (2) the contribution of
RVLM BBS type 1 receptors (BB1) to the maintenance of hypertension in SHR.
Urethane-anesthetized rats (1.2 g · kg−1, i.v.) were instrumented to record mean arterial
pressure (MAP), diaphragm (DIA) motor, and renal sympathetic nerve activity (RSNA). In
NT rats and SHR, BBS (0.3 mM) nanoinjected into RVLM increased MAP (33.9 ± 6.6
and 37.1 ± 4.5 mmHg, respectively; p < 0.05) and RSNA (97.8 ± 12.9 and 84.5 ±
18.1%, respectively; p < 0.05). In SHR, BBS also increased DIA burst amplitude (115.3
± 22.7%; p < 0.05). BB1 receptors antagonist (BIM-23127; 3mM) reduced MAP (–19.9
± 4.4mmHg; p < 0.05) and RSNA (−17.7 ± 3.8%; p < 0.05) in SHR, but not in NT
rats (−2.5 ± 2.8mmHg; −2.7 ± 5.6%, respectively). These results show that BBS can
evoke sympathoexcitatory and pressor responses by activating RVLM BB1 receptors.
This pathwaymight be involved in themaintenance of high levels of arterial blood pressure
in SHR.
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INTRODUCTION
Bombesin (BBS), a tetradecapeptide isolated from the skin
of the frog Bombina bombina (Anastasi et al., 1971), have
shown broad spectrum of biological activities (Brown, 1983;
Gonzalez et al., 2008; Jensen et al., 2008). The BBS activates
three G protein-coupled receptors: bombesin receptor 1 (BB1),
bombesin receptor 2 (BB2), and bombesin receptor 3 (BB3).
BBS-like peptides—Neuromedin B (NB) and gastrin releasing
peptide (GRP) are natural ligand of the BB1 and BB2 receptors,
respectively (Jensen et al., 2008). Natural agonist of the BB3
receptor still remains unknown. However, it seems that BB3
receptor plays an important physiological role, since BB3 receptor
knockout mice developed obesity associated with hypertension
and impairment of glucose metabolism (Ohki-Hamazaki et al.,
1997). In human, the BB1 receptor gene is at chromosome
6p21-pter (Jensen et al., 2008). The BB1 receptor signal occurs
primarily through phospholipase-C-mediated cascades, that
involve activation of Gqα protein and consequent stimulation of
protein kinase C (Jensen et al., 2008).
In mammals, BBS receptors and BBS-like peptides are
distributed in the Central Nervous System (CNS) (Woodruff
et al., 1996; Jensen et al., 2008) including regions involved in the
cardiorespiratory control (Chung et al., 1989; Lynn et al., 1996;
Li et al., 2016). The administration of BBS has been reported
to enhancebreathing (Holtman et al., 1983; Glazkova and
Inyushkin, 2006), raise plasma concentration of catecholamine
(Brown and Fisher, 1984), tachycardia (Zogovic and Pilowsky,
2011), increase blood pressure (Brown, 1983; Zogovic and
Pilowsky, 2011), and sympathetic tone (Zogovic and Pilowsky,
2011) in normotensive (NT) rats. Zogovic and Pilowsky (2011)
showed that intrathecal injection of BBS is associated with
sympathoexcitatory and pressor responses. In the same study, the
authors also reported that the administration of an antagonist of
BBS receptor 2 attenuated the effects of BBS on blood pressure of
NT rats. However, the involvement of the rostral ventral medulla
(RVLM) in the BBS-induced cardiorespiratory and autonomic
responses as well as the contribution of the BBS receptor type 1 to
the maintenance of blood pressure in NT rats and spontaneously
hypertensive rats (SHR) is still unclear.
The RVLM contains neurons that regulate peripheral
sympathetic vasomotor tone and blood pressure (Guertzenstein,
1973; Guertzenstein and Silver, 1974; Guyenet et al., 1989;
Guyenet, 2006; Toney and Stocker, 2010). The RVLM is localized
ventral to the rostral part of the nucleus ambigus (NA), caudal
to the facial nucleus and ventral to the Bötzinger complex. The
RVLMneurons project to the sympathetic preganglionic neurons
located in the intermediolateral (IML) cell column of the spinal
cord (Loewy, 1981; Millhorn and Eldridge, 1986; Guyenet, 2006).
The neurons projecting from RVLM could modulate peripheral
sympathetic activity to the kidneys, vessels, heart, and adrenal
gland.
The hyperactivity of RVLM neurons has been implicated
in the maintenance of hypertension in different experimental
models (Yang et al., 1995; Fink, 1997; Ito et al., 2000, 2003;
Matsuura et al., 2002; Adams et al., 2007; Stocker et al., 2007;
Toney and Stocker, 2010). Previous studies have shown that the
injection of excitatory amino acid (EAA) antagonist into the
RVLM reduced arterial pressure in SHR but not in NT rats (Ito
et al., 2000). In addition, the electrophysiological studies have
shown that firing rate of RVLM neurons is significantly faster
in neonatal and adult SHR than NT rats (Chan et al., 1991;
Matsuura et al., 2002). These findings indicate that hyperactivity
of the RVLM neurons could contribute to the development and
maintenance of hypertension in SHR.
Hence, we hypothesized whether or not the injection of BBS
into RVLM affects cardiorespiratory and sympathetic activities
in NT rats and SHR. In order to test this hypothesis, the
recording of themean arterial pressure (MAP), renal sympathetic
nerve activity (RSNA) and diaphragm (DIA) motor activity were
carried out to evaluate changes induced by unilateral and bilateral
injection of BBS into RVLM of urethane-anesthetized NT rats
and SHR. In addition, the contribution of tonic activation of BBS
receptor 1 in the maintenance of high levels of arterial pressure
in SHR was also evaluated.
METHODS
Animals and Ethical Approval
Male Wistar NT rats and SHR weighing 250 to 330 g were used.
Animals were housed in a temperature-controlled room (22–
24◦C) with a 12:12-h light-dark cycle (lights on at 07:00), free
access to food, and tap water. All experimental procedures were
designed in strict adherence to the National Health Institute
Guidelines for Care and Use of Laboratory Animals, and
approved by Ethics Committee for Animal Care and Use (CEUA)
of the Federal University of Goiás (number of ethical committee:
025/12).
Surgical Procedures
Rats were anesthetized with halothane (2–3% in O2; Tanohalo;
Cristália, SP, Brazil). The right femoral vein and artery were
catheterized for drug administration and blood pressure
recording, respectively. After catheterization, anesthesia
was maintained by intravenous administration of urethane
(1.2 g · kg−1 b.wt.; Sigma–Aldrich, St. Louis, MO, USA). The
trachea was cannulated to reduce airway resistance. Bipolar
stainless steel electrodes were implanted in the DIA muscle
for electromyography (EMG) recording of inspiratory motor
activity. Rats were later mounted prone in a stereotaxic apparatus
for craniotomy and instrumented for the recording of RSNA.
The body temperature of rats was maintained at 37± 0.5◦C with
a thermostatically controlled heated table.
Recording of Cardiorespiratory Parameters
In order to record the arterial pressure, the arterial catheter
was connected to a pressure transducer which is coupled to
an amplifier (Bridge Amp FE221; ADInstruments, Colorado
Springs, CO, USA). The pulsatile pressure was recorded
continuously with a data acquisition system (PowerLab;
ADInstruments, Colorado Springs, CO, USA). The MAP
was calculated from the pulsatile signal using the LabChart
software (v.7.3.7, ADInstruments, Colorado Springs, CO, USA).
Analogical signals of the electrocardiogram (ECG), obtained
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through electrodes positioned in the forelimbs, were amplified
1000 times and filtered between 100 and 1000 Hz (Bridge Amp;
ADInstruments, Colorado Springs, CO, USA). The heart rate
(HR) was calculated as instantaneous frequency of the ECG
signal (LabChart v.7.3.7, ADInstruments, Colorado Springs,
CO, USA). The DIA motor activity signals was amplified 10,000
times (Bridge Amp; ADInstruments, Colorado Springs, CO,
USA) and band-pass filtered (100–2000Hz). The signal were
rectified and integrated in 50ms intervals using LabChart
software (v.7.3.7; ADInstruments, Colorado Springs, CO, USA).
The DIA motor activity was evaluated by burst amplitude
(expressed as percentage difference from baseline) and frequency
(considered as respiratory frequency, fR, and expressed in cycles
per minute, cpm).
Recording of Renal Sympathetic Nerve
Activity
RSNA was recorded through the left renal nerve with bipolar
silver electrodes. The renal nerve was located, dissected
and covered with mineral oil prior to the placement of
electrodes for recording (Nujol - Schering-Plough, São Paulo,
SP, Brazil). The signals were obtained using a high-impedance
probe connected to the amplifier (P511; Grass Instruments,
Quincy, MA, USA). The signal was amplified 20,000 times,
digitized and band-pass filtered (30–1000 Hz). The nerve
signal was recorded continuously (with a PowerLab System-
ADInstruments; Colorado Springs, CO, USA), rectified and
integrated at 1 s intervals using LabChart software (v.7.3.7.;
ADInstruments; Colorado Springs, CO, USA). At the end of each
experiment, ganglionic blocker hexamethonium (30mg · kg−1,
b.wt., i.v.; Sigma–Aldrich, St. Louis, MO, USA) was administered
to determine the background noise. The level of RSNA was
expressed as a percentage of baseline after subtraction of the
noise.
Respiratory Synchronization
Analyses of the respiratory synchronization were made oﬄine
using Spike2 software (version 8; Cambridge Electronic Design
Limited, Cambridge, CAM, England). In order to analyze
respiratory modulation, RSNA was rectified and signals were
smoothed using a time constant of 50 ms. The DIA-triggered
averages of RSNA were generated after nanoinjection of vehicle
and bilateral BBS into RVLM. Averages of RSNA were made
using 15 DIA burst as trigger events. The time of inspiration was
determined based on the duration of the inspiratory DIA burst
while expiratory time was determined between consecutive DIA
burst. The RSNA post-inspiratory peak was later evaluated.
Nanoinjections into RVLM
Animals were mounted prone in a stereotaxic apparatus (David
Kopf Instruments, Tujunga, CA, USA) with incisor bar 11 mm
below the interaural line. After partial removal of the occipital
bone, the meninges covering the dorsal surface of the brainstem
was opened up surgically to visualize the calamus scriptorius.
In order to nanoinject into the RVLM, a glass micropipette
was positioned as follows: 2.5mm rostral from the calamus
scriptorius,±2.0 mm lateral from the midline and 2.5mm ventral
from the dorsal surface.
Firstly, RVLM was localized through unilateral nanoinjection
(50 nl) of L-glutamate (10 mM; Sigma-Aldrich, St. Louis,
MO, USA) in all experimental groups. RVLM was considered
previously identified when L-glutamate nanoinjection increased
MAP in approximately 20 mmHg. After the return of
cardiorespiratory and sympathetic activities to basaline, the
bilateral nanoinjection (50 nl each) of vehicle (150 mM NaCl;
Sigma-Aldrich, St. Louis, MO, USA), BBS (0.3 mM; Bachem
AG, Bubendorf, Switzerland) or bombesin receptor 1 (BB1)
antagonist (3 mM; [D-2- NaI5-Cys6,11-Tyr7,D-Trp8,Val10,2-
NaI12-Somatostatin-14 (5–12) amide trifluoroacetate salt]; BIM-
23127; Bachem AG, Bubendorf, Switzerland) was injected into
RVLM. In order to confirm the integrity of RVML, L-glutamate
(10 mM; 50 nl) was nanoinjected again. This nanoinjection
produced similar increase in MAP (∼20 mmHg) as previously
observed in the initial L-glutamate nanoinjection.
Histology
At the end of the experiment, 2% Evans Blue solution (50
nl; Sigma-Aldrich, St. Louis, MO, USA) was nanoinjected
bilaterally into RVLM for histological analyses with the aim of
confirming the accuracy of injection sites. Rats were perfused
transcardially with saline (150mM NaCl; 300mL), followed by
10% formaldehyde (300 mL; Synth Ltda, Diadema, SP, Brazil).
The brains were later removed and fixed in 10% formaldehyde.
Frozen brains were cut into 40 µm coronal sections and stained
with 1% neutral red to determine the nanoinjection sites.
Experimental Protocols
The MAP, DIA motor activity and RSNA were recorded (NT,
n = 7; SHR, n = 7). After a period of stabilization, bilateral
nanoinjections of BBS (0.3 mM in 50 nl each) or equivalent
volume of vehicle (150 mMNaCl in 50 nl each) was nanoinjected
into RVLM. In another group of NT rats (n= 6) and SHR (n= 6),
BIM-23127 (BB1 receptor antagonist; 3 mM in 50 nl each) was
nanoinjected bilaterally into RVLM. In order to confirm the
blockade of BB1 receptors, in separated groups of NT rats (n =
3) and SHR (n = 6), unilateral nanoinjection of BBS (0.3 mM in
50 nl each) 15 min before and 15 min after BIM-23127 (3 mM in
50 nl each) was carried out.
Statistical Analysis
The GraphPad Prism software (v.6; GraphPad Software, Inc.,
La Jolla, CA, USA) was used for the statistical analysis
of experimental data. The basal values and changes in the
respiratory synchronization induced by BBS nanoinjection were
compare between the groups using an unpaired and paired
Student’s t-test. The autonomic and cardiovascular effects
induced by nanoinjection of vehicle, BBS, and BIM into the
RVLM were analyzed using two-way ANOVA prior to the
Newman–Keuls test. The value of p < 0.05 was considered
statistically significant.
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RESULTS
Histological Analysis
Figure 1A show a representative photomicrograph of the
brainstem section that indicates the accuracy of nanoinjection
site—RVLM. The center of the nanoinjection site distributions
at rostral and caudal levels of RVLM are shown in Figure 1B.
Only animal with RVLM confined nanoinjections were
analyzed.
Cardiorespiratory and Sympathetic
Changes Produced by the Injections of
BBS into RVLM
Table 1 shows the body weight and basal values of MAP, RSNA,
and fR of NT rats and SHR. There were no changes in RSNA and
body weight among groups. However, higher MAP and lower fR
were observed in SHR when compared with NT rats (p< 0.05).
Unilateral nanoinjection of L-glutamate into RVLM increased
MAP in both NT rats (1MAP: 21.6 ± 5.6 mmHg vs. vehicle
−0.7 ± 0.5 mmHg; p < 0.05) and SHR (26.3 ± 6.3 mmHg vs.
vehicle 0.4 ± 0.5 mmHg; p < 0.05; Figures 2, 3A). The injection
of L-glutamate did not elicit significant alteration in RSNA, DIA
burst amplitude and fR in NT rats (1RSNA: 28.8 ± 5.2% vs.
vehicle −0.3 ± 1.1%; 1DIA Burst Amp: −19.9 ± 15.3% vs.
vehicle −0.5 ± 1.7%; 1fR: −6.7 ± 8,2 cpm vs. vehicle −2,5 ±
1.8 cpm; Figures 2, 3C,D) and SHR (1RSNA: 40.0 ± 3.2% vs.
vehicle 1.4 ± 0.6%; 1DIA Burst Amp: 10.7 ± 12% vs. vehicle
−3.5 ± 1.6%;1fR: −3.5 ± 2.4 cpm vs. vehicle −0.03 ± 1.2 cpm;
Figures 2, 3B–D).
Unilateral nanoinjection of BBS increased MAP in NT rats
(17.1 ± 1.7 mmHg vs. vehicle −0.7 ± 0.3 mmHg; p < 0.05;
Figures 2A, 3A) without significant change in RSNA (45.5 ±
6.9% vs. vehicle −0.3 ± 1.1%; Figures 2A, 3B), DIA burst
amplitude (21.3± 6.1% vs. vehicle−0.5± 1.7%; Figures 2A, 3C)
and fR (−0.1 ± 3.7 cpm vs. vehicle −2.5 ± 1.8 cpm; Figures 2A,
3D). In SHR, unilateral nanoinjection of BBS increased MAP
(28.8 ± 3.2 mmHg vs. vehicle 0.3 ± 0.4 mmHg; p < 0.05;
Figures 2B, 3A) without significant alteration in RSNA (31.8 ±
3.7% vs. vehicle 1.4 ± 0.6%; Figures 2B, 3B) and fR (11.9 ±
3.5 cpm vs. vehicle 0.0 ± 1.2 cpm; Figures 2B, 3D). Unilateral
nanoinjection of BBS enhanced DIA burst amplitude (81.2 ±
37.9% vs. vehicle−3.5± 1.5%; p< 0.05; Figures 2B, 3C).
In NT rats, bilateral nanoinjection of BBS increased MAP
(33.9 ± 6.6; 27.8 ± 2.9; 16.8 ± 3.4 mmHg vs. vehicle −0.7 ± 0.3
mmHg at 1, 5, and 15 min, respectively; p < 0.05; Figures 2A,
3A) and RSNA (97.8 ± 12.9; 73.1 ± 23.2; 66.9 ± 30.2% vs.
vehicle −0.3 ± 1.1%, at 1, 5, and 15 min, respectively; p < 0.05;
Figures 2A, 3B). An increase inMAP (37.1± 4.6; 26.2± 5.2; 19.5
± 5.5 mmHg vs. vehicle 0.3 ± 0.4 mmHg, at 1, 5, and 15 min,
respectively; p < 0.05; Figures 2B, 3A) and RSNA (87.9 ± 18.1;
68.7 ± 16.8% vs. vehicle 1.4 ± 0.6%, at 1 and 5 min, respectively;
p< 0.05; Figures 2B, 3B) were observed in SHR.
FIGURE 1 | RVLM nanoinjection site. Photomicrograph of a coronal section of the medulla showing a representative site of injection labeled with 4% Evans Blue
dye into RVLM (arrow; A). Schematic drawing showing the center of the nanoinjection site to the bregma in normotensive (open circles) and hypertensive (closed
circles) rats nanoinjected with either bombesin (0.3mM) or BIM-23127 (3mM; B), and rats that received unilateral nanoinjection of bombesin before and after
BIM-23127. NA, nucleus ambiguous.
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TABLE 1 | Body weight (b.w) and basal values of mean arterial pressure (MAP), renal sympathetic nerve activity (RSNA), and respiratory frequency (fR) of
normotensive (NT) and spontaneously hypertensive rats (SHR) that received nanoinjections of bombesin (BBS; 0.3mM) or BIM-23127 (3mM) into RVLM.
Groups Injection b.w (g) MAP (mmHg) RSNA (a.u.) fR (cpm)
NT I BBS 294.7 ± 4.9 86.3 ± 5.6 0.052 ± 0.02 95.9 ± 3.1
NT II BIM-23127 287.1 ± 6.7 92.4 ± 5.1 0.061 ± 0.01 96.1 ± 6.5
NT III BBS-BIM-BBS 284 ± 4.2 108.1 ± 8.9 0.123 ± 0.01 102.8 ± 11.4
SHR I BBS 275.7 ± 3.8 127.6 ± 2.1* 0.107 ± 0.02 66.0 ± 1.9*
SHR II BIM-23127 288.1 ± 7.1 126.6 ± 3.1* 0.163 ± 0.05 69.3 ± 3.4*
SHR III BBS-BIM-BBS 291.1 ± 5.2 127.0 ± 2.9* 0.110 ± 0.02 70.8 ± 5.5*
Values are expressed as mean ± SEM. *different from normotensive groups; p < 0.05. n = 3–7.
FIGURE 2 | Examples showing the cardiorespiratory and sympathetic effects induced by BBS into RVLM. Digitized record of cardiovascular, sympathetic,
and respiratory responses produced by unilateral nanoinjections of L-glutamate (10 mM; 50 nl), vehicle (150 mM NaCl), unilateral bombesin (BBS; 0.3 mM), bilateral
bombesin (BBS; 0.3 mM; 1, 5, and 15 min) into RVLM of normotensive (A) and hypertensive rats (B). Pulsatile arterial pressure (PAP), renal sympathetic nerve activity
(RSNA), integrate of renal sympathetic nerve activity (
∫
RSNA), integrate of diaphragm motor activity (
∫
DIAEMG) and hexam (hexamethonium).
The DIA burst amplitude was not altered by bilateral
nanoinjections of BBS in NT rats (23.2 ± 3.3; 19.3 ± 6.0; 15.3 ±
17.3% vs. vehicle −0.5 ± 1.7%; at 1, 5, and 15 min, respectively;
Figures 2A, 3C). On the other hand, bilateral nanoinjections
of BBS increased DIA burst amplitude in SHR (111.0 ± 25.3;
94.5 ± 23.1; 90.9 ± 27.7% vs. vehicle −3.5 ± 1.5%; at 1,
5, and 15 min, respectively; p < 0.05; Figures 2B, 3C). The
bilateral nanoinjection of BBS did not induce significant changes
in fR of NT rats (−5.1 ± 9.3; −2.6 ± 7.4 cpm; −2.4 ± 6.4
vs. vehicle −2.5 ± 1.8 cpm; at 1, 5, and 15 min, respectively;
Figures 2A, 3D) and SHR (10.5 ± 9.1; 8.7 ± 8.9; 15.4 ± 9.2
cpm vs. vehicle 0.0 ± 1.2 cpm; at 1, 5, and 15 min, respectively;
Figures 2B, 3D).
The unilateral nanoinjection of BBS did not elicit significant
alteration in HR of NT rats (−14.5 ± 4.9 bpm vs. vehicle
−3.2 ± 1.6 bpm). The bilateral nanoinjection of BBS decreased
HR (−30.1 ± 7.3 bpm; −27.0 ± 6.8 bpm; −23.9 ± 6.8 bpm vs.
vehicle −3.2 ± 1.6 bpm; at 1, 5, and 15 min, respectively; p <
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FIGURE 3 | Cardiovascular, sympathetic, and respiratory responses
induced by bombesin naoinjected into RVLM. Changes induced by
unilateral nanoinjecton of L-glutamate (Glut, 10 mM; 50 nl), vehicle (Veh, 150
mM NaCl), bombesin (I BBS, 0.3 mM), and bilateral nanoinjection of bombesin
(II BBS; 0.3 mM; 1, 5, and 15 min) into RVLM on mean arterial pressure (MAP;
A), renal sympathetic nerve activity (RSNA; B), diaphragm burst amplitude (DIA
Burst Amp; C) and respiratory frequency (fR; D) in normotensive and
hypertensive rats. *different from vehicle; †different from normotensive rats.
p < 0.05; n = 7.
0.05). In SHR, the unilateral (18.4 ± 3.8 bpm vs. vehicle −8.5 ±
1.9 bpm; p < 0.05) and bilateral nanoinjections of BBS (26.3 ±
7.0 bpm; 27.4 ± 7.7 bpm; 25.8 ± 8.2 bpm vs. vehicle −8.5 ± 1.9
bpm; at 1, 5, and 15 min; respectively; p< 0.05) increased HR.
Synchronization of Sympathetic Discharge
During the Respiratory Cycle after Bilateral
Nanoinjection of BBS into RVLM
The BBS nanoinjected into RVLM elicited an increase in post-
inspiratory RSNA peak in SHR (0.309± 0.07 a.u vs. vehicle 0.180
± 0.05 a.u.; p< 0.05; Figure 4B) but not in NT rats (0.227± 0.06
a.u vs. vehicle 0.103± 0.05 a.u.; Figure 4A).
Cardiorespiratory and Sympathetic
Changes Produced by BB1 Receptor
Blockade in the RVLM Neurons in NT rats
and SHR
The bilateral nanoinjection of BIM-23127 into RVLM did not
produce significant changes in MAP (−2.2 ± 2.8; −1.4 ± 2.7;
−2.4 ± 1.9 mmHg vs. vehicle 1.0 ± 1.0 mmHg, at 1, 5, and 15
min, respectively; Figures 5A, 6A), RSNA (−2.9 ± 2.5; −3.4 ±
2.7; −3.3 ± 2.3% vs. vehicle 0.0 ± 0.9% at 1, 5, and 15 min,
respectively; Figures 5A, 6B), DIA burst amplitude (−0.7 ± 3.5;
−0.5 ± 3.1; −3.7 ± 3.5% vs. vehicle 2.1 ± 3.5% at 1, 5, and 15
min, respectively; Figures 5A, 6C) and fR (−0.1 ± 1.9; −4.0 ±
4.2; −7.8 ± 4.1 cpm vs. vehicle −1.1 ± 1.1 cpm at 1, 5, and 15
min, respectively; Figures 5A, 6D) in NT rats.
In SHR, bilateral nanoinjection of BIM-23127 reduced MAP
(−19.9± 4.4;−14.8± 4.6;−15.6± 4.1 mmHg vs. vehicle−0.0±
1.2 mmHg, at 1, 5, and 15 min respectively; p< 0.05; Figures 5B,
6A) and RSNA (−17.7 ± 3.8; −11.3 ± 2.4; −12.4 ± 3.5% vs.
vehicle 0.7 ± 1.0% at 1, 5, and 15 min, respectively; p < 0.05;
Figures 5B, 6B). No significant changes were observed in the
DIA burst amplitude (−10.5± 5.9; –14.0± 5.4;−11.8± 5.9% vs.
vehicle 1.5 ± 2.9% at 1, 5, and 15 min, respectively; Figures 5B,
6C) and fR (−2.3 ± 3.5; −2.2 ± 3.5; −2.7 ± 3.0 cpm vs. vehicle
−4.6± 2.2 cpm at 1, 5, and 15 min, respectively; Figures 5B, 6D)
in SHR.
The blockade of BB1 receptor did not alter HR in both NT rats
(−3.8 ±3.0 bpm; −4.9 ± 2.4 bpm; −7.8 ± 2.6 bpm vs. vehicle
1.9± 1.6 bpm, at 1, 5, and 15 min, respectively) and SHR (−11.5
±6.7 bpm;−6.1± 5.0 bpm;−5.7± 6.2 bpm vs. vehicle 0.4± 1.2
bpm, at 1, 5, and 15 min, respectively).
Cardiorespiratory and Sympathetic
Responses to BBS Injected after Blockade
of RVLM BB1 Receptors
Table 2 shows the cardiorespiratory and sympathetic changes
induced by unilateral nanoinjection of BBS into RVLM before
and after injection of BIM-23127 (BB1 receptor antagonist) in
NT rats and SHR. In both groups, the BBS-induced increase in
MAP and RSNA was abolished by BIM-23127. The significant
changes in BBS-induced DIA burst amplitude was abolished by
the blockade of BB1 receptors SHR.
DISCUSSION
Previous studies have shown that BBS increases blood pressure
(Brown and Guyenet, 1985; Zogovic and Pilowsky, 2011) and
sympathetic tone (Zogovic and Pilowsky, 2011). However, these
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FIGURE 4 | Effects of bilateral nanoinjection of bombesin into RVLM on respiratory synchronization of RSNA. Respiratory modulation after bilateral
nanoinjection of vehicle (150 mM NaCl) and bombesin (BBS; 0.3 mM) into RVLM of normotensive (A) and hypertensive rats (B). Examples show three respiratory
cycles. The gray boxes show the expiratory phase. Maximum amplitude of renal sympathetic nerve activity (RSNA) during post-inspiratory are present in the graphics.
*Different from vehicle. p < 0.05; n = 7.
TABLE 2 | Changes in the mean arterial pressure (MAP), renal sympathetic nerve activity (RSNA) and diaphragm burst amplitude (DIA burst Amp) induced
by unilateral injection of bombesin (BBS; 0.3 mM) into RVLM before and after BB1 receptor blockade with BIM-23127 (3 mM) in normotensive (NT) and
spontaneously hypertensive (SHR) rats.
Group Nanoinjections 1 MAP (mmHg) 1 RSNA (%) 1 DIA burst Amp (%)
NT BBS before BIM-23127 25.2 ± 0.5 47.3 ± 9.1 20.1 ± 8.7
BBS after BIM-23127 1.5 ± 0.5* 2.1 ± 0.9* −5.9 ± 7.2
SHR BBS before BIM-23127 24.8 ± 2.9 41.6 ± 4.6 24.6 ± 5.5
BBS after BIM-23127 6.5 ± 0.6* 4.7 ± 1.0* −0.1 ± 4.3*
Values are expressed as mean ± SEM. *different from BBS before BIM-23127; p < 0.05. n = 3–6.
studies did not established the effects of BBS in the brainstem
and their role in the maintenance of hypertension. In the
present study, we provided the first evidence that BBS acting
in RVLM elicits a significant increase in MAP and RSNA of
both NT rats and SHR. In addition, the administration of
BBS into RVLM increased DIA burst amplitude and post-
inspiratory RSNA burst in SHR. The blockade of BB1 receptors
in the RVLM reduces MAP and RSNA in SHR but not in NT
rats. These results strongly indicate that the sympathoexcitation
associated with pressor response to BBS administration is
mediated by BB1 receptors that are located on RVLM neurons.
It has been suggested that tonic activation of BB1 receptors
is involved in the maintenance of high arterial pressure
in SHR.
Zogovic and Pilowsky (2011), showed a long-lasting increase
in the splanchnic SNA (sSNA), blood pressure and phrenic
nerve amplitude by the intrathecal injection of BBS. Glazkova
and Inyushkin (2006) reported that microinjection of BBS in
the solitary tract nucleus (NTS) stimulated respiration, and
increased the level of pulmonary ventilation, respiratory volume,
and bioelectrical activity of the inspiratory muscles. Our results
showed that BBS injected into the RVLM increased arterial
blood pressure and sympathetic vasomotor tone in both NT and
SHR. This result suggests a modulatory action of BBS in RVLM
neurons.
Recently, Li et al. (2016) showed that small neural
subpopulation is involved in the control of breathing.
The retrotrapezoid nucleus/parafacial respiratory group
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FIGURE 5 | Examples showing the cardiorespiratory and sympathetic effects induced by BB1 receptors blockade in the RVLM. Digitized record of
cardiovascular, sympathetic and respiratory responses produced by vehicle (150 mM NaCl) and bilateral nanoinjection of BIM-23127 (3 mM; BB1 receptor antagonist;
1, 5, and 15 min after BIM) into RVLM in normotensive (A) rats and hypertensive rats (B). Pulsatile arterial pressure (PAP), renal sympathetic nerve activity (RSNA),
integrate of renal sympathetic nerve activity (
∫
RSNA) and integrate of diaphragm motor activity (
∫
DIAEMG) and hexam (hexamethonium).
(RTN/pFRG) expresses neuromedin B (BBS-like peptide genes)
and GRP. This neural subpopulation project to preBötzinger
Complex (preBötC, the respiratory rhythm generator that
expresses neuromedin B and GRP receptors). The vasomotor
presympathetic neurons in all anteroposterior extension of
RVLM are intercalated with ventral respiratory column neurons
(Smith et al., 2007; Alheid and McCrimmon, 2008; Wang et al.,
2009). As a result of the proximity with respiratory neurons, the
BBS injection into the RVLM could activate neuromedin B or
GRP receptors and contribute to the increase in respiratory drive
that was observed in SHR.
The RVLM neurons play essential role in the generation
of sympathetic outflow (Guertzenstein, 1973; Guyenet, 2006;
Wang et al., 2009) and regulation of peripheral chemosensitive
and barosensitive sympathetic efferents (Sun and Reis, 1995;
Miyawaki et al., 1996; Dampney et al., 2002; Alheid and
McCrimmon, 2008). The neuronal activity of the RVLM is
determined by the action of excitatory and inhibitory synapses
that involve glutamate and γ-aminobutyric acid (GABA)
neurotransmitters, respectively (Sun and Reis, 1995; Miyawaki
et al., 1996; Ito et al., 2000; Schreihofer et al., 2000; Alheid
and McCrimmon, 2008). In addition, some neuropeptides
have been reported to play important modulatory role in the
integration cardiovascular responses (Ito et al., 2000; Alheid and
McCrimmon, 2008; Abbott and Pilowsky, 2009).
Several studies have shown that the activation or blockade of
neuropeptide receptors could cause a long-term response (Abbott
and Pilowsky, 2009; Zogovic and Pilowsky, 2011). The nature of
response can be explained (partly) by the receptor-ligand type.
For instance, the sensitization of G-protein coupled receptors are
related to a wide range of intracellular event cascades such as
changes in ion channel permeability, activation of kinases, and
protein phosphorylation (Springell et al., 2005a,b).
Zogovic and Pilowsky (2011) reported that intrathecal
injection of BBS elicited gradual increase in MAP and splanchnic
sympathetic nerve activity (sSNA) within 5 min. This increase
returned to control level after approximately 35 min of BBS
injection. In our study, we showed that BBS injection into
RVLM caused a rapid increase in blood pressure. This increase
persisted during 15 min of bilateral nanoinjection of BBS. The
injection of BIM induced rapid decrease in the MAP and RSNA
(the decrease was maintained during 15 min). Some authors
have reported instantaneous response to BBS administration
(Erspamer et al., 1972; Chahl and Walker, 1981; Bayorh and
Feuerstein, 1985; Kaczynska and Szereda-Przestaszewska, 2011).
Intravenous administration of BBS caused immediate increase in
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FIGURE 6 | Cardiovascular, sympathetic, and respiratory responses
induced by BB1 receptors blockade into RVLM. Changes produced by
bilateral nanoinjecton of vehicle (150 mM NaCl) and BIM-23127 (3 mM; BB1
receptor antagonist; 1, 5, and 15 min) into RVLM on mean arterial pressure
(MAP; A), renal sympathetic nerve activity (RSNA; B), diaphragm burst
amplitude (DIA Burst Amp; C), and respiratory frequency (fR; D) in
normotensive and hypertensive rats. *different from vehicle; †different from
normotensive rats. p < 0.05; n = 6.
MAP of anesthetized animals (Erspamer et al., 1972; Kaczynska
and Szereda-Przestaszewska, 2011). According to the author,
this cardiovascular response appeared to be mediated via α-
adrenergic receptors (Kaczynska and Szereda-Przestaszewska,
2011).
Experimental evidences have demonstrated that an increase
in RVLM neuronal activity could contribute to the development
and maintenance of hypertension in SHR (Smith and Barron,
1990; Yang et al., 1995; Matsuura et al., 2002; Ito et al., 2003). The
bicuculline (GABAa receptor antagonist) injection into RVLM
slightly increased the arterial blood pressure in SHR when
compared to NT rats. This result suggest excessive excitatory
drive of RVLM pre-sympathetic neurons in hypertensive rats
(Smith and Barron, 1990). The inhibition of glutamatergic
neurotransmission by kynurenic acid (KYN) injection into
RVLM of SHR decreased the arterial pressure (Ito et al., 2000).
Matsuura et al., (2002), showed that basal membrane potential
in irregularly firing RVLM neurons is less negative in neonatal
SHR. In consequence, the RVLM neurons in these animals are
more easily excitable. The firing rate is faster in neonatal SHR
when compared with NT rats. In our study, we demonstrated
that the blockade of RVLM BB1 receptors decreased MAP and
RSNA in SHR, but not in NT rats. These findings suggest that the
activation of BB1 receptors in the RVLM could have contributed
to the maintenance of high arterial pressure in SHR.
Our findings are consistent with previous studies, which
showed a decrease blood pressure of anesthetized hypertensive
rats as a result of pharmacological blockade of RVLM neurons
(Bergamaschi et al., 1999, 2014; Ito et al., 2000, 2003; Suhaimi
et al., 2010; Du et al., 2013). The BBS injection into RVLM,
in the present study, induced similar increase in the MAP
and RSNA of SHR when compared with NT rats. The
anesthesia reduced MAP in hypertensive rats more than in NT
controls. Unlike non-anesthetized rats, the subjection of rats to
anesthesia is assumed to have prevented the some responses
to BBS.
Our results showed that BBS injection into RVLM induced
sympathoexcitation with an increase in the blood pressure
of NT rats and SHR. This effect indicates that RVLM could
integrate neuronal pathway that are involved in BBS induced
cardiorespiratory and sympathetic effects. The blockade of BB1
receptors in the RVLM of SHR, but not NT rats, decreased MAP
and RSNA. This result suggests that the tonic activation of BB1
receptors is involved in the maintenance of high blood pressure
in anesthetized SHR. The changes in the cardiorespiratory and
sympathetic activity as a result of an activation or inhibition of
RVLM BBS receptors suggests an important cardiorespiratory
role of BBS and related peptides.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments: GP, CD, AF, AD,
AR, DC. Performed the experiments: ID, AM, SM, AC, KG.
Analyzed the data: ID, AM, ED, MF, JF, DC, EC, GP. Contributed
reagents/materials/analysis tools: DC, CD, DR, EC, AF, AD, AR,
GP. Wrote the paper: ID, AM, ED, MF, JF, DR, EC, AF, AR, GP.
ACKNOWLEDGMENTS
This work was supported by Fundação de Amparo a Pesquisa
do Estado de Goiás (FAPEG) grants 2012/0055431086 (GP)
and 2009/10267000352 (GP) and by Conselho Nacional de
Desenvolvimento Científico e Tecnológico (CNPq) grants
477832/2010-5 (GP), 483411/2012-4 (GP), and 447496/2014-0
Frontiers in Physiology | www.frontiersin.org 9 June 2016 | Volume 7 | Article 205
Pinto et al. BB1 Receptors and Hypertension
(GP). The funders had no role in study design, data collection,
analysis, decision to publish, or preparation of the manuscript.
Moreover, all authors have contributed sufficiently in this study
to be included as authors.
REFERENCES
Abbott, S. B., and Pilowsky, P. M. (2009). Galanin microinjection into rostral
ventrolateral medulla of the rat is hypotensive and attenuates sympathetic
chemoreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1019–R1026.
doi: 10.1152/ajpregu.90885.2008
Adams, J. M., Madden, C. J., Sved, A. F., and Stocker, S. D. (2007). Increased
dietary salt enhances sympathoexcitatory and sympathoinhibitory responses
from the rostral ventrolateral medulla. Hypertension 50, 354–359. doi:
10.1161/HYPERTENSIONAHA.107.091843
Alheid, G. F., and McCrimmon, D. R. (2008). The chemical neuroanatomy of
breathing. Respir. Physiol. Neurobiol. 164, 3–11. doi: 10.1016/j.resp.2008.07.014
Anastasi, A., Espamer, V., and Bucci, M. (1971). Isolation and structure of
bombesin and alytesin, two analogous active peptides from the skin of the
European amphibians Bombina and Alytes. Experientia 27, 166–167.
Bayorh, M. A., and Feuerstein, G. (1985). Bombesin and substance P modulate
peripheral sympathetic and cardiovascular activity. Peptides 6(Suppl. 1),
115–120. doi: 10.1016/0196-9781(85)90019-1
Bergamaschi, C. T., Campos, R. R., and Lopes, O. U. (1999). Rostral
ventrolateral medulla: a source of sympathetic activation in rats subjected
to long-term treatment with L-NAME. Hypertension 34, 744–747. doi:
10.1161/01.HYP.34.4.744
Bergamaschi, C. T., Silva, N. F., Pires, J. G., Campos, R. R., and Neto, H. A.
(2014). Participation of 5-HT and AT1 receptors within the rostral ventrolateral
medulla in the maintenance of hypertension in the goldblatt 1 kidney-1 clip
model. Int. J. Hypertens. 2014:723939. doi: 10.1155/2014/723939
Brown, M. R. (1983). Central nervous system sites of action of bombesin and
somatostatin to influence plasma epinephrine levels. Brain Res. 276, 253–257.
doi: 10.1016/0006-8993(83)90732-1
Brown, M. R., and Fisher, L. A. (1984). Brain peptide regulation of adrenal
epinephrine secretion. Am. J. Physiol. 247, E41–E46.
Brown, M. R., and Guyenet, P. G. (1985). Electrophysiological study of
cardiovascular neurons in the rostral ventrolateral medulla in rats. Brain Res.
549, 118–126. doi: 10.1161/01.res.56.3.359
Chahl, L. A., and Walker, S. B. (1981). Responses of the rat cardiovascular
system to substance P, neurotensin and bombesin. Life Sci. 29, 2009–2015. doi:
10.1016/0024-3205(81)90611-1
Chan, R. K., Chan, Y. S., and Wong, T. M. (1991). Electrophysiological
properties of neurons in the rostral ventrolateral medulla of normotensive and
spontaneously hypertensive rats. Brain Res. 549, 118–126. doi: 10.1016/0006-
8993(91)90607-W
Chung, K., Briner, R. P., Carlton, S. M., and Westlund, K. N. (1989).
Immunohistochemical localization of seven different peptides in the human
spinal cord. J. Comp. Neurol. 280, 158–170. doi: 10.1002/cne.902800111
Dampney, R. A., Coleman, M. J., Fontes, M. A., Hirooka, Y., Horiuchi, J., Li, Y. W.,
et al. (2002). Central mechanisms underlying short- and long-term regulation
of the cardiovascular system. Clin. Exp. Pharmacol. Physiol. 29, 261–268. doi:
10.1046/j.1440-1681.2002.03640.x
Du, D., Chen, J., Liu, M., Zhu, M., Jing, H., Fang, J., et al. (2013). The
effects of angiotensin II and angiotensin-(1-7) in the rostral ventrolateral
medulla of rats on stress-induced hypertension. PLoS ONE 8:e70976. doi:
10.1371/journal.pone.0070976
Erspamer, V., Melchiorri, P., and Sopranzi, N. (1972). The action of bombesin on
systemic arteria blood pressure of some experimental animals. Br. J. Pharinc.
45, 442–450. doi: 10.1111/j.1476-5381.1972.tb08100.x
Fink, G. D. (1997). Long-term sympatho-excitatory effect of angiotensin II:
a mechanism of spontaneous and renovascular hypertension. Clin. Exp.
Pharmacol. Physiol. 24, 91–95. doi: 10.1111/j.1440-1681.1997.tb01789.x
Glazkova, E. N., and Inyushkin, A. N. (2006). Respiratory reactions to
microinjection of bombesin into the solitary tract nucleus and their
mechanisms. Neurosci. Behav. Physiol. 36, 403–408. doi: 10.1007/s11055-006-
0031-y
Gonzalez, N., Moody, T. W., Igarashi, H., Ito, T., and Jensen, R. T. (2008).
Bombesin-related peptides and their receptors: recent advances in their role in
physiology and disease states. Curr. Opin. Endocrinol. Diabetes Obes. 15, 58–64.
doi: 10.1097/MED.0b013e3282f3709b
Guertzenstein, P. G. (1973). Blood pressure effects obtained by drugs applied
to the ventral surface of the brain stem. J. Physiol. 229, 395–408. doi:
10.1113/jphysiol.1973.sp010145
Guertzenstein, P. G., and Silver, A. (1974). Fall in blood pressure produced from
discrete regions of the ventral surface of the medulla by glycine and lesions. J.
Physiol. 242, 489–503. doi: 10.1113/jphysiol.1974.sp010719
Guyenet, P. G. (2006). The sympathetic control of blood pressure. Nat. Rev.
Neurosci. 7, 335–346. doi: 10.1038/nrn1902
Guyenet, P. G., Haselton, J. R., and Sun,M. K. (1989). Sympathoexcitatory neurons
of the rostroventrolateral medulla and the origin of the sympathetic vasomotor
tone. Prog. Brain Res. 81, 105–116. doi: 10.1016/S0079-6123(08)62002-6
Holtman, J. R. Jr., Jensen, R. T., Buller, A., Hamosh, P., Taveira Da Silva, A. M., and
Gillis, R. A. (1983). Central respiratory stimulant effect of bombesin in the cat.
Eur. J. Pharmacol. 90, 449–451. doi: 10.1016/0014-2999(83)90571-X
Ito, S., Hiratsuka, M., Komatsu, K., Tsukamoto, K., Kanmatsuse, K.,
and Sved, A. F. (2003). Ventrolateral medulla AT1 receptors support
arterial pressure in dahl salt-sensitive rats. Hypertension 41, 744–75. doi:
10.1161/01.HYP.0000052944.54349.7B
Ito, S., Komatsu, K., Tsukamoto, K., and Sved, A. F. (2000). Excitatory amino acids
in the rostral ventrolateral medulla support blood pressure in spontaneously
hypertensive rats. Hypertension 35, 413–417. doi: 10.1161/01.HYP.35.1.413
Jensen, R. T., Battey, J. F., Spindel, E. R., and Benya, R. V. (2008). International
union of pharmacology. LXVIII. mammalian bombesin receptors:
nomenclature, distribution, pharmacology, signaling, and functions in
normal and disease states. Pharmacol. Rev. 60, 1–42. doi: 10.1124/pr.107.07108
Kaczynska, K., and Szereda-Przestaszewska, M. (2011). Vasopressor
and heart rate responses to systemic administration of bombesin in
anesthetized rats. Pharmacol. Rep. 63, 448–454. doi: 10.1016/S1734-1140(11)
70511-4
Li, P., Janczewski, W. A., Yackle, K., Kam, K., Pagliardini, S., Krasnow, M. A., et al.
(2016). The peptidergic control circuit for sighing. Nature 530, 293–297. doi:
10.1038/nature16964
Loewy, A. D. (1981). Descending pathways to sympathetic and parasympathetic
preganglionic neurons. J. Auton. Nerv. Syst. 3, 265–275. doi: 10.1016/0165-
1838(81)90068-0
Lynn, R. B., Hyde, T. M., Cooperman, R. R., and Miselis, R. R. (1996). Distribution
of bombesin-like immunoreactivity in the nucleus of the solitary tract and
dorsal motor nucleus of the rat and human: colocalization with tyrosine
hydroxylase. J. Comp. Neurol. 369, 552–570.
Matsuura, T., Kumagai, H., Kawai, A., Onimaru, H., Imai, M., Oshima, N.,
et al. (2002). Rostral ventrolateral medulla neurons of neonatal wistar-
kyoto and spontaneously hypertensive rats. Hypertension 40, 560–565. doi:
10.1161/01.HYP.0000032043.64223.87
Millhorn, D. E., and Eldridge, F. L. (1986). Role of ventrolateral medulla in
regulation of respiratory and cardiovascular systems. J. Appl. Physiol. 61,
1249–1263.
Miyawaki, T., Minson, J., Arnolda, L., Llewellyn-Smith, I., Chalmers, J.,
and Pilowsky, P. (1996). AMPA/kainate receptors mediate sympathetic
chemoreceptor reflex in the rostral ventrolateral medulla. Brain Res. 726, 64–68.
Ohki-Hamazaki, H., Watase, K., Yamamoto, K., Ogura, H., Yamano, M., Yamada,
K., et al. (1997). Mice lacking bombesin receptor subtype-3 develop metabolic
defects and obesity. Nature 390, 165–169. doi: 10.1038/36568
Schreihofer, A. M., Stornetta, R. L., and Guyenet, P. G. (2000). Regulation of
sympathetic tone and arterial pressure by rostral ventrolateral medulla after
depletion of C1 cells in rat. J. Physiol. 529(Pt 1), 221–236. doi: 10.1111/j.1469-
7793.2000.00221.x
Smith, J. C., Abdala, A. P., Koizumi, H., Rybak, I. A., and Paton, J. F. (2007). Spatial
and functional architecture of the mammalian brain stem respiratory network:
Frontiers in Physiology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 205
Pinto et al. BB1 Receptors and Hypertension
a hierarchy of three oscillatory mechanisms. J. Neurophysiol. 98, 3370–3387.
doi: 10.1152/jn.00985.2007
Smith, J. K., and Barron, K. W. (1990). GABAergic responses in ventrolateral
medulla in spontaneously hypertensive rats. Am. J. Physiol. 258,
R450–R456.
Springell, D. A., Costin, N. S., Pilowsky, P. M., and Goodchild, A. K. (2005a).
Hypotension and short-term anaesthesia induce ERK1/2 phosphorylation in
autonomic nuclei of the brainstem. Eur. J. Neurosci. 22, 2257–2270. doi:
10.1111/j.1460-9568.2005.04413.x
Springell, D. A., Powers-Martin, K., Phillips, J. K., Pilowsky, P. M.,
and Goodchild, A. K. (2005b). Phosphorylated extracellular signal-
regulated kinase 1/2 immunoreactivity identifies a novel subpopulation
of sympathetic preganglionic neurons. Neuroscience 133, 583–590. doi:
10.1016/j.neuroscience.2005.02.036
Stocker, S. D., Meador, R., and Adams, J. M. (2007). Neurons of the rostral
ventrolateral medulla contribute to obesity-induced hypertension in rats.
Hypertension 49, 640–646. doi: 10.1161/01.HYP.0000254828.71253.dc
Suhaimi, F. W., Yusoff, N. H., Dewa, A., and Yusof, A. P. (2010). Role of
excitatory amino acid input in rostral ventrolateral medulla neurons in rats with
obesity-induced hypertension. Acta Neurol. Belg. 110, 57–64.
Sun, M. K., and Reis, D. J. (1995). NMDA receptor-mediated sympathetic
chemoreflex excitation of RVL-spinal vasomotor neurones in rats. J. Physiol.
482(Pt 1), 53–68. doi: 10.1113/jphysiol.1995.sp020499
Toney, G. M., and Stocker, S. D. (2010). Hyperosmotic activation of CNS
sympathetic drive: implications for cardiovascular disease. J. Physiol. 588,
3375–3384. doi: 10.1113/jphysiol.2010.191940
Wang, W. Z., Gao, L., Wang, H. J., Zucker, I. H., and Wang, W.
(2009). Tonic glutamatergic input in the rostral ventrolateral medulla is
increased in rats with chronic heart failure. Hypertension 53, 370–374. doi:
10.1161/HYPERTENSIONAHA.108.122598
Woodruff, G. N., Hall, M. D., Reynolds, T., and Pinnock, R. D. (1996). Bombesin
receptors in the brain. Ann. N.Y. Acad. Sci. 780, 223–243. doi: 10.1111/j.1749-
6632.1996.tb15126.x
Yang, T. L., Chai, C. Y., and Yen, C. T. (1995). Enhanced sympathetic reactivity
to glutamate stimulation in medulla oblongata of spontaneously hypertensive
rats. Am. J. Physiol. 268, H1499–H1509.
Zogovic, B., and Pilowsky, P. M. (2011). Intrathecal bombesin is
sympathoexcitatory and pressor in rat. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 301, R1486–R1494. doi: 10.1152/ajpregu.00297.2011
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Pinto, Mourão, da Silva, Camargo, Marques, Gomes, Fajemiroye,
da Silva Reis, Rebelo, Ferreira-Neto, Rosa, Freiria-Oliveira, Castro, Colombari,
Colugnati and Pedrino. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 11 June 2016 | Volume 7 | Article 205
